Ryan Gregg, PhD

Ryan Gregg, PhD has a diverse work experience in the pharmaceutical and healthcare industry. Ryan has worked as a Senior Medical Science Liaison at Ironshore since 2019, where they provide medical support and education to healthcare professionals interested in Ironshore's Delexis Drug Delivery technology and their FDA-approved medication for ADHD, Jornay PM. Prior to this, they worked as a Medical Science Liaison at Braeburn from 2018 to 2019, supporting the opioid use disorder pipeline product, CAM2038. From 2016 to 2018, they served as a Medical Science Liaison for OneOme, focusing on the adoption of RightMed pharmacogenomic testing in the US East Coast and international markets. During their time at OneOme, they also developed collaborations for clinical studies with elite healthcare systems such as Cleveland Clinic and Moffitt Cancer Center. Before that, they worked as a Senior Medical Writer and then as a Medical Writer at Oxford PharmaGenesis in 2016. In addition, they have a background in academia, having completed their Doctoral Candidacy in Pharmacology at Temple University School of Medicine from 2011 to 2015, with a research focus on behavioral neuropharmacology. Ryan has also worked as a Research Associate at Rho, Inc. in 2010 and as a GC/MS Technologist at LabCorp: Laboratory Corporation of America in 2010. Ryan started their career as a Lab Technician at USDA-ARS in 2009 and as a Lab Intern at the North Carolina Office of the Chief Medical Examiner-Toxicology Lab also in 2009. Furthermore, they worked as a Contract Worker at Smith & Nephew Orthopaedics in 2008.

Ryan Gregg, PhD received their Bachelor of Science degree with Honors in Forensic Chemistry from the University of Mississippi from 2006 to 2010. Ryan continued their education at the Temple University - Lewis Katz School of Medicine and obtained their Doctor of Philosophy (Ph.D.) in Pharmacology from 2011 to 2015.